重组DNA
冠状病毒
受体
病毒
生物
肺
病毒学
血管紧张素转化酶2
蛋白质亚单位
糖蛋白
免疫学
医学
内科学
分子生物学
2019年冠状病毒病(COVID-19)
基因
疾病
生物化学
传染病(医学专业)
作者
Koro Gotoh,Fumiko Satoh,Honami Uesugi,T. Noguchi,Naoki Matsuda,Kentaro Sada,Shotaro Miyamoto,Yoshinori Ozeki,Yuichi Yoshida,Mitsuhiro Okamoto,Takayuki Masaki,Toshiaki Kawabe,Hirotaka Shibata
标识
DOI:10.1096/fj.202301864rr
摘要
Abstract Coronavirus disease 2019 (COVID‐19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Obesity is a major risk factor for the development of COVID‐19. Angiotensin‐converting enzyme 2 (ACE2) is an essential receptor for cell entry of SARS‐CoV‐2. The receptor‐binding domain of the S1 subunit (S1‐RBD protein) in the SARS‐CoV‐2 spike glycoprotein binds to ACE2 on host cells, through which the virus enters several organs, including the lungs. Considering these findings, recombinant ACE2 might be utilized as a decoy protein to attenuate SARS‐CoV‐2 infection. Here, we examined whether obesity increases ACE2 expression in the lungs and whether recombinant ACE2 administration diminishes the entry of S1‐RBD protein into lung cells. We observed that high‐fat diet‐induced obesity promoted ACE2 expression in the lungs by increasing serum levels of LPS derived from the intestine. S1‐RBD protein entered the lungs specifically through ACE2 expressed in host lungs and that the administration of recombinant ACE2 attenuated this entry. We conclude that obesity makes hosts susceptible to recombinant SARS‐CoV‐2 spike proteins due to elevated ACE2 expression in lungs, and this model of administering S1‐RBD protein can be applied to new COVID‐19 treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI